Vertex Pharmaceuticals, Inc (NASDAQ: VRTX) on Monday, plunged -2.30% from the previous trading day, before settling in for the closing price of $408.76. Within the past 52 weeks, VRTX’s price has moved between $377.85 and $519.88.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 27.16%. The company achieved an average annual earnings per share of -96.66%. With a float of $256.90 million, this company’s outstanding shares have now reached $257.74 million.
Considering the fact that the conglomerate employs 5400 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 86.1%, operating margin of -2.96%, and the pretax margin is 2.45%.
Vertex Pharmaceuticals, Inc (VRTX) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Vertex Pharmaceuticals, Inc is 0.24%, while institutional ownership is 92.75%. The most recent insider transaction that took place on Nov 15 ’24, was worth 7,178. In this transaction EVP, Chief Scientific Officer of this company sold 15 shares at a rate of $478.56, taking the stock ownership to the 25,813 shares. Before that another transaction happened on Nov 15 ’24, when Company’s Officer proposed sale 15 for $478.56, making the entire transaction worth $7,178.
Vertex Pharmaceuticals, Inc (VRTX) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of 4.35 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -96.66% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 12.20% during the next five years compared to 11.42% growth over the previous five years of trading.
Vertex Pharmaceuticals, Inc (NASDAQ: VRTX) Trading Performance Indicators
Vertex Pharmaceuticals, Inc (VRTX) is currently performing well based on its current performance indicators. A quick ratio of 2.20 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 9.69.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.99, a number that is poised to hit 4.02 in the next quarter and is forecasted to reach 18.60 in one year’s time.
Technical Analysis of Vertex Pharmaceuticals, Inc (VRTX)
Compared to the last year’s volume of 1.24 million, its volume of 1.54 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 29.48%. Additionally, its Average True Range was 13.74.
During the past 100 days, Vertex Pharmaceuticals, Inc’s (VRTX) raw stochastic average was set at 15.14%, which indicates a significant decrease from 21.80% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 53.17% in the past 14 days, which was higher than the 31.78% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $462.68, while its 200-day Moving Average is $457.50. Nevertheless, the first resistance level for the watch stands at $404.78 in the near term. At $410.21, the stock is likely to face the second major resistance level. The third major resistance level sits at $413.07. If the price goes on to break the first support level at $396.49, it is likely to go to the next support level at $393.63. Should the price break the second support level, the third support level stands at $388.20.
Vertex Pharmaceuticals, Inc (NASDAQ: VRTX) Key Stats
Market capitalization of the company is 102.84 billion based on 257,529K outstanding shares. Right now, sales total 9,869 M and income totals 3,620 M. The company made 2,772 M in profit during its latest quarter, and 1,045 M in sales during its previous quarter.
